Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Word on the street says that TRZN is going to take JANE out.
When I click on your link to the otcmarkets I get a 404 page not found error. I'm guessing TRZN has already taken JANE out.
You will remember this time
Thanks Professor, I agree, great post by Maverick0408. After reading that, I scrolled down through a few more posts and found the above post by Angel_rayo and thought it worth the read.
Don 4X, so, you're saying that a doctor who goes through all of the same medical training as, let's say a primary care doctor, but then decides to take that training further and specialize in a particular area by advancing their knowledge and skills suddenly become useless in all the other areas? Wow, who knew?
Okay, that's funny.
Excellent job Killery.
daemon57, lol, nice...thx for sharing that. :)
Well done Bill_Eng...thanks for sharing that.
You missed the point of my post. I was merely responding to mjbaker's post:
I google searched FDA SRO list. Found a link to the full list that is searchable. I searched "CYDY" and found Cytodyn listed:
https://www.accessdata.fda.gov/scripts/SDA/sdNavigation.cfm?filter=CYDY&sortColumn=1a&sd=srolist&page=1&previewMode=true
(sigh) In other words, the FDA can say "We will grant you an EUA but there are conditions to the EUA and they are as follows...." They can do this as they see fit in the granting of an EUA.
Perhaps you could do the validation yourself if you have thousands of dollars betting on this drug? Perhaps contact the company and ask for clarification....just a thought.
It's been my assumption that EUAs are, by their very nature, conditional or temporary while awaiting a full FDA approval or even potential denial, depending on the outcome of whatever trials are occurring. It's a stop gap measure issued for Emergency Use. Given the safety rating of LL and known efficacy, I can't see any valid reason for not granting the EUA. The whole "conditional" verbiage, in my opinion, is a case of semantics. But, hey, if you're not comfortable with all the vast amount of information provided thus far and you feel the need to perform additional validation, feel free and share the results if you're so inclined.
AstraZeneca may have included "outdated and potentially misleading data" that overstated the effectiveness of its Covid vaccine
https://www.newsbreakapp.com/n/0Z0fiqDG?share_id=eyJ1c2VyaWQiOjQ0MDQ2Nzk2LCJkb2NfaWQiOiIwWjBmaXFERyIsInRpbWVzdGFtcCI6MTYxNjUyMTA5NDcyMH0=&share_destination_id=NDQwNDY3OTYtMTYxNjUyMTA5OTA2OA==&s=a4&pd=02yoaCTE&hl=en_US
GoodBuyBill, as far as I'm aware, nobody stated the unconditional EUA was rejected.
This feels a bit like:
Bill_ENG, that's what I thought too. I think I misunderstood what NP wrote when I wrote that question:
That's great to hear. Thanks for sharing that info.
First, thank you for sharing that docj. Not sure I understand the need for conditional EUA if a full unconditional EUA is already in place. Wouldn't the unconditional EUA negate the need for a conditional EUA?
Great catch Daemon57 and great job getting that noticed and a correction on the way.
Daemon57, I was wondering the same thing but then again, given the particular affliction for which they are studying, longhaulers, perhaps the intent is to see LONG term how well they do. In otherwords, maybe they get better right away but 3 month, 6 months and longer the symptoms recur? If so, then does that mean they receive another injection and then continue to monitor even longer? Hard to say without more information.
Excellent, great news moneycrew. Glad to hear this and thanks for taking this on!
I've never seen one shred of actual proof to back up those allegations. Wish I knew why. There must be a good reason, though I can't think of one.
Well written post moneycrew. I assume you'll have some print-outs of the facts to share with your contact so that he'll be able to further review and do any other research he deems appropriate before passing along what he's learned from you. Powerful stuff...thanks for your efforts!
Well-crafted and good use of your one post. Thanks!
SizzlChest, I can appreciate the general sentiment of what you're saying, I do have one area I would like to address.
bryguy19, in response to your comment, have you read this yet? Perhaps this may provide you a fresh perspective. I would encourage you to read this article in its entirety. It provides some solid information that may encourage you with respect to Leronlimab's potential re: Covid-19.
Important information from Steven F. Hotze, M.D. on the Dangers of the So-Called COVID-19 "Vaccine". Source links can be found in Dr. Hotze's article on https://crtxnews.com/
The So-Called COVID-19 "Vaccine"
I wonder if Dr Hotze is aware of Leronlimab and its MOA, safety and effectiveness as a therapeutic?
TP, that's a good point. I'd forgotten that. So yeah, he already had one CC this week and although he wants to have one every week or two that will only happen with attorneys' approval. Thanks for reminding me. I guess he hasn't failed to keep his word with respect to CCs.
March 8th was a CC. What were you looking for, 2 CCs in the first week? Plus, I believe he said a CC every 1 or 2 weeks? Would need to review it again but that's what I recall.
Assuming that March 11th was the day that the 20th Longhauler was enrolled and dosed and if the rate of Longhaulers trial enrollments remains constant, 2 per day, then we should have our final enrollee 15 days later, which will be March 26th.
Four weeks of safety evaluation then puts the next target date as April 23rd. The PR then says the endpoint measure would be at day 56. I'm not sure if that means 56 days after the safety evaluation is complete or after the last enrollee. If 56 days is after last enrollee then the endpoint measure completion date is May 21st, otherwise it will be June 18th.
If the final enrollee date changes from the anticipated date of March 26th, then add or subtract the number of days difference to either March 26th or April 23rd, whichever is the correct endpoint measure day.
Thanks, but the market giveth and the market taketh away, at least for aw little while. Hopefully today's red candle that we're currently seeing turns into a wick to a green candle. If not, I believe it's just the normal rhythm of an up and down cycle with hopefully more ups than downs from this point forward. Regardless, I believe it's going to need a catalyst to push us up very far. There are many catalysts on watch right now.
D-Mike, yes, they are just starting a longhauler trial. I know there is one going on in Florida but I don't know where else it may also be taking place, if any. I would contact Cytodyn directly and inquire.
Contact
I wish I could give you better information. I know I've read lots on here about the longhauler study as well as other places online. I'm sure that the folks at Cytodyn can direct you on what to do. I think info@cytodyn.com would be one way to initiate or call 360-980-8524. You can also email npourhassan@cytodyn.com and skelly@cytodyn.com.
Don't wait.
GLTU!!
Sukus, I think that's a wise approach.
Here's my previous post in response to Tryn2. Just some things to consider:
So, Nader was responsible for placing the over 65's in the Leronlimab arm of the trial, thus causing it to fail? Hmm, interesting 'theory'.... I wasn't aware the CEO of a biotech has so much control over a blind study. Who knew?
BWA, wondering if you're out. You stated you had a stop in at 2.25.
Tryn2, this was destined to happen if we didn't meet or exceed the primary end point. Between all the doom and gloom relating to company management and/or share price predictions around failure to meet the primary end point and lack of EUA/full FDA approval, this was inevitable.
Also consider that even though the news was actually very positive, some simply haven't yet grasped the full significance of what we've learned. The reality of the remarkable results will slowly gain more footing as more and more analysis is shared and confidence combined with understanding in the drug increases. This will then result in increased share price as those who got scared out of their investment realize that maybe they jumped the gun a bit too soon. Many of them will then attempt to get back in at the best price they can. This will become increasingly difficult as more and more gain understanding with respect to what Leronlimab is able to do. The worse may not yet be over if predictions from a few are to be believed. However, those lower prices won't live there forever.
It's unfortunate that things have played out like they have for so many who are in severe and critical need. Many will never survive and many will want answers that they may never get. The only thing we can be sure of based on what we now know is that this painful wait will not be forever, at least in my opinion. I think this spring/summer will prove to be a major turning point for everyone who desperately need this drug and for Cytodyn shareholders.
Hold strong to your knowledge and belief in the science and ignore the noise. The noise will do nothing good for you, NOTHING.
Evil Rabbit, I assume it would be the same blinded trial. I hadn't considered that the OLE would apply to the additional 140 additional enrollees. If that's true then this won't take nearly as long.
I couldn't find anything about CYDY in that thread and I scrolled for what seemed like forever opening up more and more of the thread and doing a 'Find' and nothing showed up.
CTMedic, wow, great read. Thanks for putting that together. I was having a difficult time trying to put it all together in a way that I could understand it and what you did really helped. I appreciate it.
CYDYWinning, I can't speak to the timing of when institutional buyers will be jumping in but, what I can say, is that institutional investors could give ZIP about all the drama. They're interested in approvals and income, period. Let's hope that we really do get their attention and soon. I have a feeling that we're on their radar now.
Bill_Eng, I agree. I honestly and truly believe that if NP were to achieve FDA approval this week and immediately sell ALL of the current supply we have and show proof of the next batch in progress and sales orders for a new supply along with an uplist approval and dividends of solid gold brick bars that there would still be folks wanting to lynch the guy. There is literally NOTHING he could do to satisfy some short of jumping out of a plane at 10k feet without a parachute. Constant nagging does wonders to enlighten new investors who might want to jump on board....yep. I wonder if some ever think about their detrimental impact to their own investment?